- Source: Seladelpar
Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis. It is used as the lysine dihydrate salt. It is a PPARδ receptor agonist. The compound was licensed from Janssen Pharmaceutica NV.
Seladelpar was approved for medical use in the United States in August 2024.
Medical uses
Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.
Clinically, Seladelpar reduces pruritus and IL-31 in patients with primary biliary cholangitis.
References
Kata Kunci Pencarian:
- Asam perfluorooktanoat
- Seladelpar
- List of drugs: Se–Sh
- Primary biliary cholangitis
- Ibuprofen
- GW501516
- Thiazolidinedione
- Fenofibrate
- Perfluorooctanoic acid
- Fibrate
- Cannabigerol
